# #133 - Vinay Prasad, M.D., M.P.H: Hallmarks of successful cancer policy

**Channel:** Peter Attia MD
**Upload Date:** 2020-10-19
**URL:** https://www.youtube.com/watch?v=1CO7Ya7FAMc
**Duration:** 132 minutes

## Description

Vinay Prasad is a practicing hematologist-oncologist who doubles as a “meta-researcher,” studying the quality of medical evidence, health policy, and clinical trials. In this episode, Vinay discusses the differences in clinical treatment from the existing medical evidence, often leading to useless, or even harmful, outcomes for patients. With a focus in oncology, he takes a deep dive into the field’s structural problems, which include the disconnect between progress and funding, drug costs, and financial conflicts of interest. He concludes with his “six hallmarks of successful cancer policy” as a potential roadmap to sustained progress against cancer and a way to avoid repeating the policy and practice mistakes of the past.

We discuss:
00:00:00 - Intro
00:03:15 - Vinay’s background and unique perspective 
00:10:15 - Medical reversal—the disconnect between research findings and clinical applications in medicine 
00:22:45 - The uniquely challenging field of oncology  
00:30:00 - The importance of bedside manner with cancer patients 
00:37:00 - Structural problems in oncology—Problem #1: Huge costs for small improvements 
00:40:15 - Structural problems in oncology—Problem #2: Medical reversal—when medical practices are adopted based on low levels of evidence 
00:45:00 - Structural problems in oncology—Problem #3: Slow progress in cancer research (despite all the hype and propaganda) 
00:54:45 - Structural problems in oncology—Problem #4: The burden of payment is not matched with those making treatment decisions 
01:06:45 - “No-brainer” moves in oncology  
01:09:30 - “Fool’s gold” treatments in oncology  
01:16:00 - The six hallmarks of successful cancer policy 
01:18:00 - Cancer policy hallmark #1: Independence  
01:28:15 - Cancer policy hallmark #2: Evidence 
01:31:30 - Cancer policy hallmark #3: Relevance 
01:32:00 - Cancer policy hallmark #4: Affordability 
01:47:00 - Cancer policy hallmark #5: Possibility 
01:52:00 - Cancer policy hallmark #6: Agenda 
01:54:30 - Tumor genome sequencing and liquid biopsies 
02:03:30 - Vinay’s clinical philosophy, being skeptical without being too contrarian, and practicing medicine without perfect information  

Show notes page: https://peterattiamd.com/vinayprasad/

About:
The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 30 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.

Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more: https://peterattiamd.com/
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Play: http://bit.ly/TheDriveGooglePlay

## AI Summary

Here's my comprehensive analysis of this episode of The Drive with Dr. Vinay Prasad:

1. **Executive Summary**:
This episode focuses on cancer policy, drug development, and the structural challenges in oncology treatment. Dr. Prasad, a hematologist-oncologist at UCSF, discusses his book "Malignant" and presents six hallmarks of successful cancer policy. The conversation covers the limitations of clinical trials, conflicts of interest in medicine, and the challenges of drug pricing and development.

2. **Key Medical/Scientific Points**:
- Clinical trial patients are typically 10 years younger and healthier than average cancer patients [1:12:45]
- Average improvement in survival for 71 consecutively approved cancer drugs was 2.1 months [0:45:30]
- Medicare makes up 25-35% of insurance payments in the US [1:45:20]
- Two-thirds of cancer drugs are approved based on tumor shrinkage rather than survival benefits [1:15:30]

3. **Health Optimization Tips**:

Universal recommendations:
- Be cautious of drugs approved solely based on tumor response rather than survival data [1:15:30]
- Consider genomic testing for specific cancers (lung, melanoma, colon) [1:55:20]

Context-specific recommendations:
- For rare tumors in younger patients, look for fusion events [1:58:15]
- Consider clinical trials when standard treatments fail [1:56:30]

4. **Supplements & Medications**:
Medications discussed:
- Gleevec for CML [0:52:30]
- Avastin for colon cancer [0:53:15]
- Keytruda for various cancers [1:59:30]

5. **Notable Quotes**:
"Science is like the greatest thing that people have ever done" [1:35:20]

"It's not the doctor's role to determine what treatment is right for someone; it's really the doctor's role to empower the patient" [2:08:15]

6. **Follow-up Questions**:
1. How can we better incentivize development of truly transformative cancer drugs?
2. What role should patient advocacy groups play in drug development?
3. How can we better balance the need for rapid drug approval with ensuring proper efficacy?

7. **References & Resources**:
Books mentioned:
- "Malignant" by Vinay Prasad [0:05:30]
- "Ending Medical Reversal" by Vinay Prasad [0:05:45]

Experts referenced:
- Jim Allison - Immunotherapy pioneer [1:38:45]
- Judah Folkman - Angiogenesis researcher [0:52:15]

This episode provides valuable insights into the challenges and potential solutions in cancer treatment and policy. The discussion of the six hallmarks offers a framework for improving cancer care delivery and research.

Let me know if you would like me to expand on any particular aspect of this analysis.
